Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Myelofibrosis: Nuancing the Potential of Disease Modification

January 12th 2023

A brief review of the biology of myelofibrosis, the potential for disease modification, and subsequent implications for treatment.

Duvelisib Wins Orphan Drug Designation for PTCL in Europe

January 10th 2023

The European Commission has issued an orphan drug designation to duvelisib for the treatment of adult patients with peripheral T-cell lymphoma.

BGB-11417 Shows Encouraging Early Efficacy and Tolerability in CLL

January 9th 2023

Chan Y. Cheah, MD, MBBS, discusses the the phase 1 BGB-11417-101 trial, which showed that the BCL-2 inhibitor BGB-11417, administered alone or in combination with the BTK inhibitor zanubrutinib, induced promising response rates and was well tolerated patients with chronic lymphocytic leukemia.

Japan Approves Acalabrutinib for Treatment-Naïve CLL

January 6th 2023

Japan’s Ministry of Health, Labor, and Welfare has approved acalabrutinib for the treatment of previously untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

FDA Grants Priority Review to Glofitamab for Relapsed/Refractory LBCL

January 6th 2023

The FDA has accepted a biologics license application for glofitamab for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy.

Therapy in Myelofibrosis: Pacritinib

January 5th 2023

Key opinion leaders on myeloproliferative neoplasms review clinical data behind pacritinib therapy in the setting of myelofibrosis.

Novel Therapy in Myelofibrosis: Momelotinib

January 5th 2023

Switching their focus to myelofibrosis management, expert panelists reflect on clinical data behind momelotinib, a novel JAK2 inhibitor.

Dr. Alvarnas on the Importance of Access to CAR T-cell Therapy in Cancer Care

January 5th 2023

Joseph Alvarnas, MD, discusses the importance of access to CAR T-cell therapy in cancer care.

Dr. Dadwal on the Investigation of Posoleucel Following Allogeneic HCT

January 5th 2023

Sanjeet Singh Dadwal, MD, discusses the investigation of posoleucel as a prevention strategy for infections in patients following an allogenic hematopoietic cell transplant.

Dr. Zakrzewski on Investigation of IT848 Nanotherapy in Hematologic Malignancies

January 5th 2023

Johannes Zakrzewski, MD, discusses the investigation of a nanoframework-based delivery system for IT848 in hematologic malignancies.

Glofitamab Plus R-CHOP Displays Tolerable Safety Profile in Treatment-Naïve DLBCL

January 3rd 2023

Max S. Topp, MD, highlights the rationale for studying bispecific antibodies in newly diagnosed diffuse large B-cell lymphoma, how the safety profile of glofitamab plus R-CHOP contributes to its potential for outpatient administration, and where future directions with this research may lead.

Waldenström Macroglobulinemia Treatment Moves Away From Chemotherapy

January 2nd 2023

The past decade has been a time of great progress in the research of Waldenström macroglobulinemia and the care of patients with the rare form of non-Hodgkin lymphoma.

DiPersio’s Altered Career Path Led to Groundbreaking Developments in Leukemia

December 26th 2022

A teenage injury cost him a career among the stars, so John F. DiPersio, MD, PhD, became a star hematologist/oncologist instead.

Japan Approves Second-line Axi-cel for LBCL

December 23rd 2022

Japan’s Ministry of Health, Labor and Welfare has approved axicabtagene ciloleucel for the initial treatment of patients with relapsed/refractory large B-cell lymphoma, including diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, transformed follicular lymphoma, and high-grade B-cell lymphoma.

Lisaftoclax With or Without Rituximab or Acalabrutinib Elicits Favorable Responses and Safety in CLL/SLL

December 23rd 2022

Lisaftoclax alone or in combination with acalabrutinib or rituximab was active across a range of doses and displayed a tolerable safety profile in patients with relapsed/refractory and treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma.

FDA Approves Mosunetuzumab for Relapsed/Refractory Follicular Lymphoma

December 23rd 2022

The FDA has approved mosunetuzumab-axgb (Lunsumio) for the treatment of adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy.

Evolution of Targeted Therapy Improves Clinical Benefit in Blood and Bone Marrow Cancers

December 22nd 2022

Edward J. Pearson, MD, and colleagues, discuss the expanded role of targeted therapies in the treatment of patients with hematologic malignancies.

Role of Symptom Burden in Thrombocythemia and Polycythemia Vera

December 22nd 2022

Shared insight on how a patient’s symptom burden can impact management strategies within essential thrombocytopenia and polycythemia vera.

Overview on Essential Thrombocythemia and Polycythemia Vera Management

December 22nd 2022

Expert perspectives on the respective treatment landscapes of essential thrombocytopenia (ET) and polycythemia vera (PV) following the ASH 2022 Annual Meeting.

Imetelstat Achieved Prolonged, Continuous Transfusion Independence in Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory to Erythropoiesis-Stimulating Agents Within the IMerge Phase 2 Study

December 22nd 2022

Dr Uwe Platzbecker reviews data on imetelstat in patients with lower-risk myelodysplastic syndromes (MDS) that were recently presented at the 2022 American Society of Hematology (ASH) Annual Meeting.